Epstein-Barr virus-associated persistent polyclonal B-cell lymphocytosis with a distinct 69-base pair deletion in the LMP1 oncogene

Annals of Hematology

Volumn 74, Issue 1, 1997, Pages 23-28

  Larcher, C ^a   McQuain, C ^b   Berger, C ^b   Mitterer, M ^c   Quesenberry, P J ^b   Huemer, H P ^a   Knecht, H ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c General Regional Hospital   (Italy)

Author keywords

Epstein Barr virus; Kindred; LMP 1; LMP 2A; Lymphocytosis

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; POLYCLONAL ANTIBODY;

ARTICLE; B LYMPHOCYTE; CARBOXY TERMINAL SEQUENCE; CASE REPORT; DELETION MUTANT; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTOSIS; NONHUMAN; ONCOGENE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SIBLING; SIGNAL TRANSDUCTION; VIRUS LATENCY;

AMINO ACID SEQUENCE; B-LYMPHOCYTES; BASE COMPOSITION; CELL LINE; EPITOPES; FEMALE; GENE DELETION; HERPESVIRUS 4, HUMAN; HLA-A ANTIGENS; HUMANS; LYMPHOCYTOSIS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, DNA; VIRAL MATRIX PROTEINS;

EID: 0031023368     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050250     Document Type: Article

References (53)

1. Alber G, Kim KM, Weiser P, Rieslerer C, Carsetti R, Reth M (1993) Molecular mimicry of the antigen receptor signaling motif by transmembrane proteins of the Epstein-Barr virus and the bovine leukaemia virus. Curr Biol 3:333-339
2. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Seguin C, Tuffnell PS, Barrell BG (1984) DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310:207-211
3. Bankier AT, Deininger PL, Satchwell SC, Baer R, Farrell PJ, Barrell GB (1983) DNA sequence analysis of the EcoRI Dhet fragment of B95-8 Epstein-Barr virus containing the terminal repeat sequences. Mol Biol Med 1:425-445
4. 2 signalling motif found in the cytoplasmic segments of the bovine leukaemia virus envelope protein and Epstein-Barr virus latent membrane protein 2A can elicit early and late lymphocyte activation. EMBO J 12:5105-5112
5. Berger C, Brousset P, McQuain C, Knecht H (1997) Deletion variants within the NF-κB activation domain of the LMP1 oncogene in acquired immunodeficiency syndrome-related large cell lymphomas, in prelymphomas and atypical lymphoproliferations. Leukemia Lymphoma (in press)
6. Berger C, McQuain C, Sullivan J, Nadal D, Quesenberry PJ, Knecht H (1996) The LMP1 30 base pair deletion variant with an in vitro enhanced oncogenic activity prevails in acute infectious mononucleosis and EBV-associated tonsillar hyperplasia (Blood 88:202) (abstract)
7. Busson P, Edwards RH, Tursz T, Raab-Traub N (1995) Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene. J Gen Virol 76:139-145
8. Carstairs KC, Francombe WH, Scott JG, Gelfand EW (1985) Persistent polyclonal lymphocytosis of B lymphocytes, induced by cigarette smoking? Lancet 1:1094
9. Chang YS, Su IJ, Chung PJ, Shu CH, Ng CK, Wu SJ, Liu ST (1995) Detection of an Epstein-Barr-virus variant in T-cell-lymphoma tissues identical to the distinct strain observed in nasopharyngeal carcinoma in the Taiwanese population. Int J Cancer 62:673-677
10. Chow KC Nacilla JQ, Witzig TE, Li CY (1992) Is persistent polyclonal B lymphocytosis caused by Epstein-Barr virus? A study with polymerase chain reaction and in situ hybridization. Am J Hematol 41:270-275
11. Fennewald S, van Santen V, Kieff E (1984) Nucleotide sequence of a mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol 51:411-419
12. Gordon DS, Jones BM, Browning SW, Spira TJ, Lawrence DN (1982) Persistent polyclonal lymphocytosis of B lymphocytes. N Engl J Med 307:232-236
13. Gruss HJ, Ulrich D, Dower SK, Hermann F, Brach MA (1996) Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-κB transcription factor. Blood 87:2443-2449
14. Hammarskjold ML, Simurada MC (1992) Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J Virol 66:6496-6501
15. Hammerschmidt W, Sugden B, Baichwal VR (1989) The transforming domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels. J Virol 63:2469-2475
16. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A (1991) Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107-1115
17. Huen DS, Henderson SA, Croom-Carter D, Rowe M (1995) The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NFκB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10:549-560
18. Kaye KM, Izumi KM, Mosialos G, Kieff E (1995) The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol 69:675-683
19. Klein C, Rothenberger S, Niemeyer C, Bachmann E, Odermatt B, Bohm N, Brandis M, Knecht H (1995) EBV-associated lymphoproliferative syndrome with a distinct 69 base-pair deletion in the LMP-1 oncogene. Br J Haematol 91:938-940
20. Knecht H, Joske DJL, Emery-Goodman A, Bachmann E, Bachmann F, Odermalt BF (1992) Expression of human recombinase activating genes (RAG-1 and RAG-2) in Hodgkin's disease. Blood 80:2867-2872
21. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, Odermatt BF, Delsol G, Pallesen G (1993) Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 82:2937-2942
22. Knecht H, Bachmann E, Joske DJL, Sahli R, Emery-Goodman A, Casanova JL, Zilic M, Bachmann F, Odermatt BF (1993) Molecular analysis of the LMP (latent membrane protein) oncogene in Hodgkin's disease. Leukemia 7:580-585
23. Knecht H, Bachmann E, Brousset P, Rothenberger S, Einsele H, Lestou VS, Delsol G, Bachmann F, Ambros PF, Odermatt BF (1995) Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene 10:523-528
24. Knecht H, Raphael M, McQuain C, Rothenberger S, Pihan G, Bachmann E, Ryan S, Kittler ELW, Quesenberry PJ, Schlaifer D, Woda BA, Brousset P (1996) Deletion variants within the NF-κB activation domain of the LMP1 oncogene prevail in AIDS-related large cell lymphomas and HIV-negative atypical lymphoproliferation. Blood 87:876-881
25. Larcher C, Fend F, Mitterer M, Prang N, Schwarzmann F (1995) Role of Epstein-Barr virus and soluble CD21 in persistent polyclonal B-cell lymphocytosis. Br J Haematol 90:532-540
26. Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, Young LS, Rowe M, Kurilla M, Rickinson AB (1993) HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 67:7428-7743
27. Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan ICM (1989) Mechanism of antigen-driven selection in germinal centres. Nature 342:929-931
28. Liu YJ, de Boutellier O, Guret C, Lebecque S, Banchereau J, Mills FC, Max EE, Martinez-Valdez H (1996) Within germinal centers, isotype switching of immunogiobulin genes occurs after the onset of somatic mutation. Immunity 4:241-250
29. Longnecker R, Kieff E (1990) A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol 64:2319-2326
30. Longnecker R, Druker B, Roberts TM, Kieff E (1991) An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J Virol 65:3681-3692
31. Martin J, Sugden B (1991) Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association. J Virol 65:3246-3258
32. Martin JM, Veis D, Korsmeyer SJ, Sugden B (1993) Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of Bcl-2. J Virol 67:5269-5278
33. Miller CL, Longnecker R, Kieff E (1993) Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes. J Virol 67:3087-3094
34. Miller CL, Burkhardt AL, Lee JH, Stealey B, Longnecker R, Bolen JB, Kieff E (1995) Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2:155-166
35. Mitchell T, Sugden B (1995) Stimulation of NF-κB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol 69:2968-2976
36. Mitterer M, Pescosta N, Fend F, Larcher C, Prang N, Schwarzmann F, Coser P, Huemer HP (1995) Chronic active Epstein-Barr virus disease in a case of persistent polyclonal B-cell lymphocytosis. Br J Haematol 90:526-531
37. Moorthy RK, Thorley-Lawson DA (1993) All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of Rat-1 fibroblasts. J Virol 67:1638-1646
38. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E (1995) The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389-399
39. Murray RJ, Kurilla MG, Brooks MJ, Thomas WA, Rowe M, Kieff E, Rickinson AB (1992) Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 176:157-168
40. Peng M, Lundgren E (1992) Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 7:1775-1782
41. Peng M, Lundgren E (1993) Transient expression of the Epstein-Barr virus LMP1 gene in chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: cell-type-independent induction of CD23, CD21, and ICAM-1. Leukemia 7:104-12
42. Perrcault C, Bolieau J, Gyger M, de Bellefeuille C, D'Angelo G, Belanger R, Lacombe M, Lavallee R, Bonny Y, Paquin M, Brochu S (1989) Chronic B-cell lymphocytosis. Eur J Haematol 42:361-367
43. Sample J, Liebowitz D, Kieff E (1989) Two related Epstein-Barr virus membrane proteins are encoded by separate genes. J Virol 63:933-937
44. Sandvej K, Peh SC, Andresen BS, Pallesen G (1994) Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: high frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas. Blood 84:4053-4060
45. Santon A, Manzanal AI, Campo E, Bellas C (1995) Deletions in the Epstein-Barr virus latent membrane protein-1 oncogene in Hodgkin's disease. J Clin Pathol Mol Pathol 48:M184-M187
46. Stein H, Mason DY, Gerdes J, et al (1985) The expression of Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848-858
47. Tissot JD, Schmidt PM, von Fliedner V, Knecht H (1991) La lymphocytose B polyclonale persistante: un syndrome lymphoproliferatif benin. Schweiz Med Wochenschr 121:1582-1584
48. Tonegawa S (1983) Somatic generation of antibody diversity. Nature 302:575-581
49. Vasef MA, Kamel OW, Chen YY, Medeiros J, Weiss LM, Abbot SD (1995) Detection of Epstein-Barr virus in multiple sites involved by Hodgkin's disease. Am J Pathol 47:1408-1415
50. Walling DM, Clark NM, Markovitz DM, et al (1995) Epstein-Barr virus coinfection and recombination in non-human immunodeficiency virus-associated oral hairy leukoplakia. J Infect Dis 171:1122-1130
51. Wang D, Liebowitz D, Kieff E (1985) An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831-840
52. Wang D, Liebowitz D, Wang F, Gregory C, Rickinson A, Larson R, Springer T, Kieff E (1988) Epstein-Barr latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 62:4173-4184
53. Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E (1990) Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64:2309-2318